Deepcell
Deepcell is a Stanford-spinout life sciences company that builds the REM-I platform, an AI-powered, label-free single-cell imaging and sorting system used by pharmaceutical companies, academic research institutions, and biotech firms to profile and isolate live cells based on high-dimensional morphological features.
- Company typePrivate
- Founded2017
- HeadquartersMenlo Park, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Deepcell does
Deepcell is a venture-backed life sciences company founded in 2017 as a spinout from Stanford University, headquartered in Menlo Park, California. The company develops and commercializes the REM-I platform, an AI-powered single-cell analysis and sorting system that combines high-resolution brightfield imaging (0.16 µm/pixel resolution, capturing up to 1,000 cells per second), gentle microfluidics, and a proprietary self-supervised deep learning model called the Human Foundation Model (HFM). The HFM extracts 115-dimensional morphological embeddings from brightfield cell images without requiring labels, stains, or destructive sample preparation, enabling researchers to classify and sort live cells based on visual phenotypes alone — an approach Deepcell brands as "morpholomics." The platform is complemented by the AXON Data Suite for cloud or on-premises data exploration and visualization, with an air-gapped REM-I OnSite variant available for regulated and data-sovereign environments.
Deepcell sells its instruments primarily through direct enterprise field sales to pharmaceutical companies, academic research institutions, and biotech firms, with a "Request a demo" motion on its website. Revenue is generated through three streams: capital equipment sales of the REM-I instrument, subscription licensing of the AXON software, and recurring sales of reagents and consumables. Pricing is quote-based and not publicly disclosed. The company is expanding commercially into international markets including China, supported by the OnSite deployment architecture for data localization. Named application areas span oncology research, pharmaceutical drug discovery, cell and gene therapy QC, cell line development, and stem cell research, with early customer references from Erasmus Medical Center, Stanford, UCSF, and Ingel Therapeutics. The company has raised approximately $98M+ across disclosed rounds, with a $73M Series B in March 2022 led by Koch Disruptive Technologies and a subsequent venture round in April 2025 led by 50Y (Fifty Years).
Deepcell firmographics
Firmographics- Name
- Deepcell
- Legal name
- Deepcell, Inc.
- Website
- https://deepcell.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Deepcell is a Stanford-spinout life sciences company that builds the REM-I platform, an AI-powered, label-free single-cell imaging and sorting system used by pharmaceutical companies, academic research institutions, and biotech firms to profile and isolate live cells based on high-dimensional morphological features.
- Ownership category
- akta.pro rank
Deepcell industry classification
Industry- Product category
- Life Sciences Instrumentation
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)
- akta.pro secondary industry
- Model Hosting, Serving & Inference Platforms (HDAAACAB)
Keywords
Where Deepcell is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Deepcell business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- REM-I Platform Sales: Sale of the REM-I instrument platform for AI-powered single cell analysis and sorting. The platform is a high-value capital equipment for research institutions and pharmaceutical companies.
- Software Licensing (AXON Data Suite): Software licensing for data analysis and visualization through the AXON Data Suite, available as cloud or on-premises deployment.
- Reagents and Consumables: Sale of reagents and consumables for the REM-I platform workflow.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels7 records
Deepcell product offering
Product offeringCore offering
Deepcell develops and sells the REM-I Platform, an integrated instrument that combines high-resolution brightfield imaging, AI-powered morphological analysis via its Human Foundation Model (HFM), and gentle label-free microfluidic sorting to classify and isolate single cells in real time. The platform is sold with the AXON Data Suite software for analysis and visualization, and is offered in a fully on-premises REM-I OnSite configuration for regulated environments. Reagents and consumables are sold alongside the instrument as recurring revenue.
Product overview
Deepcell offers the REM-I Platform as its core product, a fully integrated cell analysis and enrichment system that combines high-resolution brightfield imaging, AI-powered morphological analysis via the Human Foundation Model (HFM), and gentle label-free sorting in a single workflow. The platform is complemented by the AXON Data Suite software for data visualization and analysis, and is available in two deployment configurations: the standard cloud-connected REM-I and REM-I OnSite for air-gapped, on-premises use in regulated environments. Deepcell also pioneered Morpholomics, a label-free approach to studying cell morphology as a high-dimensional biological readout, and is developing GenAI capabilities to interpret the HFM latent space and integrate with other omics modalities.
Differentiator
Problem solved
Functional benefit
Products and services
- REM-I Platform A fully integrated AI-powered cell analysis and sorting platform that combines high-resolution brightfield imaging (0.16 µm/pixel), the Human Foundation Model for real-time morphological analysis, and gentle label-free microfluidic sorting to classify and isolate viable single cells in one workflow. Targeted at pharmaceutical companies, academic research institutions, and biotech firms conducting drug discovery, oncology research, cell therapy QC, and basic cell biology.
- REM-I OnSite An air-gapped, on-premises deployment configuration of Deepcell's AXON Data Suite software that runs entirely on the REM-I instrument with no cloud dependency. Designed for pharmaceutical organizations with stringent data governance policies, GxP-regulated facilities, and international placements requiring data sovereignty, enabling complete run management, analysis, and visualization while keeping all data local.
- AXON Data Suite Integrated cloud and on-premises software solution for exploring, analyzing, visualizing, and managing data and runs from the REM-I platform. Enables annotation of cells and morphotypes, stores and reviews single-cell images, and provides two-way communication with the REM-I instrument for image capture and sorting. Targeted at research scientists and bioinformaticians using the REM-I platform in pharmaceutical and academic settings.
Quantifiable outcome
- Over 1 million single-cell profiles generated per experiment
- +3 more outcomes
Companies that use Deepcell
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles3 records
Deepcell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Deepcell partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Stanford UniversitycoreDeepcell originated from Stanford University research labs and was spun out from Stanford in 2017. Ongoing relationship with Stanford researchers including Scientific Advisory Board member Euan Ashley and continued collaboration on research.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Deepcell competitors and assessment
Company assessmentDirect peers
- 10x Genomics: 10x Genomics is a leading provider of single-cell analysis instruments and consumables (Chromium, Visium, Xenium). It is the most direct competitor to Deepcell in single-cell profiling workflows for pharma and academic research.
- Cytek Biosciences: Cytek provides advanced flow cytometry and cell sorting instruments used widely in immunology, oncology, and cell therapy research. Its spectral flow platforms overlap with Deepcell's cell phenotyping and sorting use cases.
- Standard BioTools (formerly Fluidigm): Standard BioTools offers mass cytometry and microfluidic single-cell analysis platforms (Hyperion, CyTOF). It competes with Deepcell in high-dimensional single-cell profiling for translational research.
- Berkeley Lights (now PhenomeX): PhenomeX (formerly Berkeley Lights) operates the Beacon optofluidic platform for single-cell functional screening and sorting, overlapping with Deepcell's label-free cell isolation and screening applications in cell therapy and antibody discovery.
- Mission Bio: Mission Bio provides single-cell multi-omics platforms (Tapestri) for genomics and proteomics at single-cell resolution, targeting oncology and pharma applications that overlap with Deepcell's translational research customer base.
Broad incumbents
- Becton, Dickinson and Company (BD): BD is a global life sciences incumbent offering flow cytometry instruments, cell sorters (FACSDiva), and reagents used across pharma and academic labs. It competes with Deepcell broadly in cell analysis but as part of a much larger portfolio.
- Bio-Techne: Bio-Techne provides a broad portfolio of life science reagents, assays, and analytical tools (including the ProteinSimple and ExoDx brands). Its cell biology and proteomics offerings overlap with Deepcell's translational and cell therapy research use cases.
- Bruker (NanoString-acquired spatial biology): Bruker, through its acquisition of NanoString's spatial biology assets, offers high-plex spatial omics platforms that overlap with Deepcell's emerging multi-omics ambitions in translational research.
Emerging players
- Parse Biosciences: Parse Biosciences offers scalable single-cell sequencing kits (Evercode) used in pharma and academic research. It competes with Deepcell indirectly by providing an alternative single-cell readout workflow.
Regional players
- Sony Biotechnology: Sony Biotechnology markets cell sorters and flow cytometry analyzers (MA900, SH800) used in research and cell therapy manufacturing, competing with Deepcell in label-free and gentle cell sorting workflows.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Deepcell social profiles
Digital presenceDeepcell financial estimates
Financial estimateRevenue estimate
Valuation estimate
Deepcell leadership team
Management profileNumber of profiles
Profiles10 records
Deepcell funding detail
Funding detailFunding overview
Funding rounds5 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Deepcell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Deepcell
What does Deepcell do?
Deepcell develops and sells the REM-I Platform, an integrated instrument that combines high-resolution brightfield imaging, AI-powered morphological analysis via its Human Foundation Model (HFM), and gentle label-free microfluidic sorting to classify and isolate single cells in real time. The platform is sold with the AXON Data Suite software for analysis and visualization, and is offered in a fully on-premises REM-I OnSite configuration for regulated environments. Reagents and consumables are sold alongside the instrument as recurring revenue.
Is Deepcell a public or private company?
Deepcell is a private company. It is classified as venture growth investor backed and is currently operating.
When was Deepcell founded?
Deepcell was founded in 2017. It employs 101 to 250 people.
Where is Deepcell based?
Deepcell is headquartered in Menlo Park, United States, in the North America region.
How does Deepcell make money?
Three revenue lines are on record. REM-I Platform Sales are the primary driver. The others are software Licensing (AXON Data Suite) and reagents and Consumables.
Who are Deepcell's main competitors?
Direct peers on record are 10x Genomics, Cytek Biosciences, Standard BioTools (formerly Fluidigm), Berkeley Lights (now PhenomeX) and Mission Bio. Broad incumbents are Becton, Dickinson and Company (BD), Bio-Techne and Bruker (NanoString-acquired spatial biology). Parse Biosciences is listed as an emerging player. Sony Biotechnology is listed as a regional player.
Does Deepcell have an API?
No public API is recorded for Deepcell.
What industry is Deepcell in?
Deepcell's product category is Life Sciences Instrumentation. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments, with a secondary code of HDAAACAB, Model Hosting, Serving & Inference Platforms. Its NAICS code is 334516 and its SIC code is 3826.